Pascal Biosciences Inc (NEVI) AI Stock Analysis

• Market Cap: C$1.39M
• Dividend Yield: N/A
• Average Volume (3M): 55.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.22
• Revenue Growth: -6.85%
• EPS Growth: 22.09%
• Country: CA
• Employees: 2
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Beverages - Non-Alcoholic
• EPS (TTM): N/A
• Shares Outstanding: 39,662,727
• 10 Day Avg. Volume: 84,932
• 30 Day Avg. Volume: 55,489
• PEG Ratio: 0.26
• Price to Book (P/B): 2.05
• Price to Sales (P/S): 1.17
• P/FCF Ratio: 31.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.03 ▼(-51.43% Downside)
• Action: Reiterated Date: 03/24/26
• Date: Action: Reiterated 03/24/26

The score is primarily constrained by ongoing unprofitability and sharp gross margin compression despite improving revenue growth and a return to positive operating/free cash flow. Technically, the stock remains in a bearish trend below major moving averages with negative MACD. Valuation provides limited support given the negative P/E and lack of dividend.

Positive Factors

Revenue Growth

Sustained acceleration in top-line growth indicates improving product traction and distribution scale. Over a 2–6 month horizon this supports revenue base expansion, helps dilute fixed costs, and increases the probability that operating leverage will convert growth into durable profitability if maintained.

Negative Factors

Ongoing Unprofitability

Despite improvement, persistent negative net margins mean the business still consumes capital and may erode equity over time. If losses persist, management will face trade-offs between investment and stabilization, increasing the chance of external funding needs that could dilute shareholders or constrain strategy.

Pascal Biosciences Inc Business Overview & Revenue Model

Company Description

Nevis Brands Inc. develops and markets cannabis products in the United States. Its flagship brand is Major, a cannabis beverage. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevi...

Read more

Nevis Brands Inc. develops and markets cannabis products in the United States. Its flagship brand is Major, a cannabis beverage. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevi...

How the Company Makes Money

null...

Pascal Biosciences Inc Financial Statement Overview

Breakdown	Nov 2025	Feb 2025	Feb 2024	Nov 2022	Feb 2022
Income Statement
Total Revenue	1.70M	1.55M	671.54K	0.00	0.00
Gross Profit	396.31K	1.08M	392.94K	-8.29K	-16.32K
EBITDA	-32.66K	-48.07K	-271.56K	-468.09K	-1.07M
Net Income	-275.07K	-362.48K	-399.77K	-480.28K	-1.09M
Balance Sheet
Total Assets	1.72M	2.04M	2.50M	18.82K	155.19K
Cash, Cash Equivalents and Short-Term Investments	102.17K	129.54K	418.52K	8.37K	0.00
Total Debt	244.21K	528.30K	683.27K	224.62K	7.76K
Total Liabilities	746.36K	813.50K	1.12M	962.93K	646.48K
Stockholders Equity	968.95K	1.23M	1.38M	-944.11K	-491.30K
Cash Flow
Free Cash Flow	62.10K	-132.06K	-390.49K	-147.68K	-614.93K
Operating Cash Flow	62.10K	-120.50K	-385.35K	-147.68K	-614.93K
Investing Cash Flow	0.00	-11.56K	-947.71K	8.98K	0.00
Financing Cash Flow	-90.20K	-167.65K	1.76M	154.84K	624.08K

Pascal Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NEVI, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.81 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NEVI.

Pascal Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
MEAT	44 Neutral	C$1.69M	-4.08	―	―	-3.76%	86.34%
NEVI	43 Neutral	C$1.39M	-7.21	-21.78%	―	-6.85%	22.09%
LFST	43 Neutral	C$1.52M	-0.82	-129.49%	―	-98.28%	76.18%